Chronic Plaque Psoriasis: Clinical Trials

19 trials for Chronic Plaque Psoriasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed. 19 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 319Completed 19

Follow Chronic Plaque Psoriasis: new trials by email Literature Review of Chronic Plaque Psoriasis trials Research Report on Chronic Plaque Psoriasis

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
Placebo, Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL1332023-10-312026-06-26
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Tildrakizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Phase 3CompletedSun Pharmaceutical Industries Limited992021-05-132026-04-01
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Topical roflumilast - Chronic Plaque Psoriasis
Phase 3CompletedArcutis Biotherapeutics, Inc.3372020-02-122026-09-09
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Roflumilast 0.3% cream, Vehicle Cream - Chronic Plaque Psoriasis
Phase 3CompletedArcutis Biotherapeutics, Inc.4392019-12-202022-12-07
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
ARQ-151 0.3% cream, ARQ-151 vehicle cream - Chronic Plaque Psoriasis
Phase 3CompletedArcutis Biotherapeutics, Inc.4422019-12-172022-12-07
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL1722018-12-202025-07-14
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL13532018-09-052026-04-15
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab, Secukinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL7432018-06-132026-04-15
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL4352018-02-052026-04-15
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab, Adalimumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL4782018-01-262026-04-15
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Bimekizumab, Ustekinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Phase 3CompletedUCB Biopharma SRL5672017-12-062026-04-15
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
M923, Humira - Chronic Plaque Psoriasis, Psoriasis
Phase 3CompletedMomenta Pharmaceuticals, Inc.5722015-09-012018-10-17
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
Placebo, secukinumab (AIN457), etanercept - Chronic Plaque Psoriasis
Phase 3CompletedNovartis Pharmaceuticals13062011-06-012021-01-05
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
adalimumab, Calcipotriol/Betamethasone Ointment, placebo (vehicle ointment) - Chronic Plaque Psoriasis
Phase 3CompletedAbbott7302007-11-012011-04-13
Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis
Cyclosporine A microemulsion, Placebo - Chronic Plaque Psoriasis
Phase 3CompletedNovartis Pharmaceuticals2432006-05-012011-08-09
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
alefacept, placebo - Chronic Plaque Psoriasis
Phase 3CompletedAstellas Pharma Inc1952003-10-012014-08-26
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
alefacept - Chronic Plaque Psoriasis
Phase 3CompletedAstellas Pharma Inc782003-07-012014-08-26
Safety and Tolerability of Repeat Courses of IM Alefacept
Alefacept - Chronic Plaque Psoriasis
Phase 3CompletedBiogen4002002-12-012023-08-23
Topical Vitamin B12 in Chronic Plaque Psoriasis
topical vitamin B12 - Chronic Plaque Psoriasis
Phase 3CompletedRuhr University of Bochum482001-01-012006-07-10

Narrower conditions

Psoriasis (10)  ·  Arthritis, Psoriatic (2)  ·  Dermatitis (1)

Broader conditions

Skin Diseases (10)  ·  Skin Diseases, Papulosquamous (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Arthritis (2)  ·  Bone Diseases (2)  ·  Joint Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Spinal Diseases (2)  ·  Spondylarthritis (2)  ·  Spondylarthropathies (2)  ·  Spondylitis (2)

Interventions

bimekizumab (7)  ·  Adalimumab (3)  ·  Alefacept (3)  ·  Roflumilast (2)  ·  secukinumab (2)  ·  Cyclosporine (1)  ·  Etanercept (1)  ·  Ustekinumab (1)  ·  Vitamin B 12 (1)  ·  betamethasone dipropionate, calcipotriol drug combination (1)  ·  calcipotriene (1)  ·  tildrakizumab (1)

Sponsors

UCB Biopharma SRL (7)  ·  Arcutis Biotherapeutics, Inc. (3)  ·  Astellas Pharma Inc (2)  ·  Novartis Pharmaceuticals (2)  ·  Abbott (1)  ·  Biogen (1)  ·  Momenta Pharmaceuticals, Inc. (1)  ·  Ruhr University of Bochum (1)  ·  Sun Pharmaceutical Industries Limited (1)

Countries

United States (15)  ·  Canada (14)  ·  Germany (11)  ·  Australia (7)  ·  Poland (7)  ·  United Kingdom (7)  ·  Belgium (6)  ·  Hungary (5)  ·  Italy (5)  ·  France (4)  ·  Russia (4)  ·  South Korea (4)  ·  Austria (3)  ·  Netherlands (3)  ·  Spain (3)

Top investigators

David Berk, MD (2)  ·  Barry Ticho, MD (1)  ·  John Caminis, MD (1)  ·  Kenneth Gordon, MD (1)  ·  Peter Altmeyer, Prof. Dr. (1)

Results publications

PMID 39578348, PMID 41060492, PMID 41800601, PMID 35544084, PMID 36751950, PMID 37950894, PMID 40286813, PMID 40886218, PMID 41359217, PMID 41580158, PMID 34260044, PMID 36125472, PMID 36422852, PMID 36689515, PMID 38588819, PMID 41134450, PMID 23178916, PMID 25007392, PMID 26267726, PMID 27573260, PMID 27576559, PMID 30972746, PMID 33549192, PMID 33549193, PMID 33748660, PMID 33891379, PMID 33891380, PMID 34001692, PMID 34110605, PMID 34471992, PMID 35133113, PMID 35305260, PMID 36648594, PMID 37182701, PMID 37341961, PMID 39285121, PMID 39862230, PMID 40156698, PMID 40788331, PMID 41678327, PMID 41706476

NIH funding

2016 (4), 2017 (1)